vimarsana.com

Page 10 - மேதிற்றின நிறுவனம் ஆஃப் மருத்துவ அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Experts recommend Covaxin for phase 2/3 trials on those aged 2-18 year

Bharat Biotech s COVID-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase II/III clinical trial on those aged between two to 18 years, official sources said. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur. The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech s application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years. After detailed deliberation, the committee recommended for conduct of proposed phase II/III clinical trial of whole virion inactivated coronavirus vaccine in the 2 to 18 years age group subject to the condition that the firm should submit the interim safety data of phase II clinical trial along with DSMB recommen

Indian council of medical researchMeditrina institute of medical sciencesCentral drugs standard control organizationExpert committeeBharat biotechMeditrina instituteMedical sciencesSubject expert committeeHyderabad based bharat biotechIndian councilMedical researchஇந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சிமேதிற்றின நிறுவனம் ஆஃப் மருத்துவ அறிவியல்மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்நிபுணர் குழுபாரத் பயோடெக்

COVID-19 Vaccine in India: Bharat Biotech s Covaxin recommended for Phase II/III trials on 2 to 18 year-olds

: Wednesday, May 12, 2021, 8:33 AM IST COVID-19 Vaccine in India: Bharat Biotech s Covaxin recommended for Phase II/III trials on 2 to 18 year-olds (Photo by AFP) While India expanded it s COVID-19 vaccination drive to include all adults at the beginning of May, children have remained excluded from both trials and the inoculation drive for the most part. That however is now set to change, with an expert panel recommending Bharat Biotech s Covaxin for phase II/III clinical trial on those aged between two to 18 years. As per reports, the trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur. The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech s application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxi

Expert committeeMeditrina institute of medical sciencesCentral drugs standard control organizationWhile indiaBharat biotechMeditrina instituteMedical sciencesSubject expert committeeHyderabad based bharat biotechநிபுணர் குழுமேதிற்றின நிறுவனம் ஆஃப் மருத்துவ அறிவியல்மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்போது இந்தியாபாரத் பயோடெக்மேதிற்றின நிறுவனம்மருத்துவ அறிவியல்

India Braces for Third COVID Wave, Allows Vaccine Trials for Children Aged 2-18

India Braces for Third COVID Wave, Allows Vaccine Trials for Children Aged 2-18 © REUTERS / ADNAN ABIDI Subscribe Sputnik International https://sputniknews.com/india/202105121082863659-india-braces-for-third-covid-wave-allows-vaccine-trials-for-children-aged-2-18/ India started vaccinating its population in the 18-45 age group earlier this month. Prior to this, only those above the age of 45 were being vaccinated. In order to protect children, federal and state governments ordered the closure of schools last March and most classes are now held online. India is preparing to save its future generation from an anticipated third wave of coronavirus that could hit children hard, warn experts. A government panel of experts on Tuesday recommended phase-2 and phase-3 clinical trials of a COVID-19 vaccine on those aged between 2 and 18 years of age.

Madhya pradeshBhavneet bhartiIndian council of medical researchMeditrina institute of medical sciencesIndia institute of medical sciencesExpert committeeGovernment medical collegeCentral drugs standard control organisationBharat biotechIndian councilMedical researchAll india instituteMedical sciencesMeditrina instituteSubject expert committeePune platform

Bharat Biotech s Covaxin recommended by expert panel for phase II / III trials on 2-18 year-olds

Bharat Biotech s Covaxin recommended by expert panel for phase II / III trials on 2-18 year-olds The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur. Share Via Email | A+A A- By PTI NEW DELHI: Bharat Biotech s COVID-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase II/III clinical trial on those aged between two to 18 years, official sources said. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur. The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech s application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years.

Indian council of medical researchExpert committeeMeditrina institute of medical sciencesCentral drugs standard control organizationBharat biotechMeditrina instituteMedical sciencesSubject expert committeeHyderabad based bharat biotechIndian councilMedical researchஇந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சிநிபுணர் குழுமேதிற்றின நிறுவனம் ஆஃப் மருத்துவ அறிவியல்மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்பாரத் பயோடெக்

vimarsana © 2020. All Rights Reserved.